SCHEMBL706818

SCHEMBL706818

CC(C)[Si](Cl)(c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.36
SLC6A2 P23975 2/20 0.36
TAAR1 Q96RJ0 2/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
CYP2A6 P11509 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
ADRA2A P08913 1/20 0.34
ADRA2C P18825 1/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
LMNA P02545 1/20 0.34
HIF1A Q16665 1/20 0.34
KDM4E B2RXH2 1/20 0.34
CYP2D6 P10635 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
NR1H2 P55055 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12815607 0.85 TACR1 (0.37) ADORA2AADORA1LMNAKDM4EALDH1A1
SCHEMBL21753773 0.82 ESR1 (0.33) MAOASLC6A2TAAR1SLC6A4SLC6A3
SCHEMBL12815713 0.81 TP53 (0.39) MAOASLC6A2TAAR1SLC6A4SLC6A3
SCHEMBL1538902 0.80 AOC3 (0.34) ESR1ESR2TDP1NR1H2NR1H3
SCHEMBL12815614 0.80 TACR1 (0.34) KDM4EALDH1A1TDP1
SCHEMBL705725 0.79 ESR1 (0.34) MAOASLC6A2TAAR1SLC6A4SLC6A3
SCHEMBL705425 0.79 ESR1 (0.34) MAOASLC6A2TAAR1SLC6A4SLC6A3
SCHEMBL1316040 0.77 ESR1 (0.38) MAOASLC6A2TAAR1SLC6A4SLC6A3
SCHEMBL1315271 0.77 LMNA (0.35) MAOASLC6A2TAAR1SLC6A4SLC6A3
SCHEMBL711378 0.74 ESR1 (0.34) MAOASLC6A2TAAR1SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4653419-A1 LINKER FOR ANTIBODY-DRUG CONJUGATES, AND ANTIBODY-DRUG CONJUGATE Otsuka Pharmaceutical Co., Ltd. (JP) 2025-11-26 EP disclosed
US-20240409519-A1 HYDROGENATED QUINOXALINES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-12-12 US disclosed
WO-2024154763-A1 LINKER FOR ANTIBODY-DRUG CONJUGATES, AND ANTIBODY-DRUG CONJUGATE 大塚製薬株式会社 2024-07-25 WO disclosed
EP-4370507-A1 HYDROGENATED QUINOXALINES Otsuka Pharmaceutical Co., Ltd. (JP) 2024-05-22 EP disclosed
CN-117616013-A Hydrogenated quinoxalines 大塚制药株式会社 2024-02-27 CN disclosed
WO-2023286768-A1 HYDROGENATED QUINOXALINES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 WO disclosed
EP-3783074-B1 COPOLYMER FOR ANTIFOULING COATING COMPOSITION AND ANTIFOULING COATING COMPOSITION CONTAINING SAID COPOLYMER NITTO KASEI CO LTD (JP) 2022-08-10 EP disclosed
EP-3783074-A1 COPOLYMER FOR ANTIFOULING COATING COMPOSITION AND ANTIFOULING COATING COMPOSITION CONTAINING SAID COPOLYMER Nitto Kasei Co., Ltd. (JP) 2021-02-24 EP disclosed
CN-111886305-A Copolymer for antifouling paint composition, and antifouling paint composition comprising same 日东化成株式会社 2020-11-03 CN disclosed
EP-2862868-B1 INTERMEDIATE FOR PRODUCTION OF NUCLEOSIDE ANALOGUE, AND METHOD FOR PRODUCING SAME DAIICHI SANKYO CO LTD (JP) 2020-04-08 EP disclosed
US-20090134789-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND NOVEL ORGANIC COMPOUND CONTAINING SILICON SUBSTITUENT FUJIFILM CORPORATION (JP) 2009-05-28 US disclosed
US-20090134789-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND NOVEL ORGANIC COMPOUND CONTAINING SILICON SUBSTITUENT FUJIFILM CORPORATION (JP) 2009-05-28 US disclosed
US-20090082585-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES BANNOU TADASHI 2009-03-26 US disclosed
US-7459577-B2 Reacting a chlorosilane with grignard reagent SHIN-ETSU CHEMICAL CO., LTD. (JP) 2008-12-02 US disclosed
US-20070213204-A1 Ziegler-Natta catalyst with in situ-generated donor NOVOLEN TECHNOLOGY HOLDINGS C.V. 2007-09-13 US disclosed
US-20070026689-A1 Silica film forming material, silica film and method of manufacturing the same, multilayer wiring structure and method of manufacturing the same, and semiconductor device and method of manufacturing the same FUJITSU LIMITED (JP) 2007-02-01 US disclosed
US-20050070730-A1 Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes SHIN-ETSU CHEMICAL CO., LTD. (JP) 2005-03-31 US disclosed
EP-1050536-A2 2-(Benz-)Imidazol-, 2-(Benz-)Oxazol- or 2-(Benz-)Thiazol-substituted Silanes Wacker-Chemie GmbH (DE) 2000-11-08 EP disclosed
US-5100762-A Radiation-sensitive polymer and radiation-sensitive composition containing the same MITSUBISHI DENKI KABUSHIKI KAISHA (JP) 1992-03-31 US disclosed
US-4996341-A Condensed bicyclic disilanylene-acetylene compound and method for preparing the same KANEGAFUCHI CHEMICAL INDUSTRY CO., LTD. (JP) 1991-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409519-A1 HYDROGENATED QUINOXALINES SLC6A3, SLC6A2, SLC18A2 MAOA 68/4885SLC6A2 2/4885TAAR1 45/4885
US-20090134789-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND NOVEL ORGANIC COMPOUND CONTAINING SILICON SUBSTITUENT L1CAM, ORC3, OR10J3 MAOA 909/4885SLC6A2 3023/4885TAAR1 1246/4885
US-20090082585-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES MLX, HAX1, RPS4X MAOA 962/4885SLC6A2 4310/4885TAAR1 209/4885
US-20050070730-A1 Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes MLX, HAX1, GRIA3 MAOA 1673/4885SLC6A2 4353/4885TAAR1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.